Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Commun ; 9(1): 3839, 2018 09 21.
Article in English | MEDLINE | ID: mdl-30242258

ABSTRACT

The Wnt signalling pathway, one of the core de-regulated pathways in chronic lymphocytic leukaemia (CLL), is activated in only a subset of patients through somatic mutations. Here we describe alternative, microenvironment-dependent mechanisms of Wnt activation in malignant B cells. We show that tumour cells specifically induce Notch2 activity in mesenchymal stromal cells (MSCs) required for the transcription of the complement factor C1q. MSC-derived C1q in turn inhibits Gsk3-ß mediated degradation of ß-catenin in CLL cells. Additionally, stromal Notch2 activity regulates N-cadherin expression in CLL cells, which interacts with and further stabilises ß-catenin. Together, these stroma Notch2-dependent mechanisms induce strong activation of canonical Wnt signalling in CLL cells. Pharmacological inhibition of the Wnt pathway impairs microenvironment-mediated survival of tumour cells. Similarly, inhibition of Notch signalling diminishes survival of stroma-protected CLL cells in vitro and disease engraftment in vivo. Notch2 activation in the microenvironment is a pre-requisite for the activation of canonical Wnt signalling in tumour cells.


Subject(s)
Bone Marrow Cells/metabolism , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Mesenchymal Stem Cells/metabolism , Receptor, Notch2/metabolism , Wnt Signaling Pathway , Animals , Cell Line , Cellular Reprogramming , Humans , Mice , Receptor Cross-Talk , beta Catenin/metabolism
2.
Blood ; 127(4): 436-48, 2016 Jan 28.
Article in English | MEDLINE | ID: mdl-26508782

ABSTRACT

The crucial dependence of chronic lymphocytic leukemia (CLL) cells on signals derived from the B cell receptor (BCR) has encouraged the development of new inhibitors, which interfere with BCR signaling and demonstrate clinical benefits in nearly all patients. In addition, signaling through Toll-like receptor (TLR) 9 of the innate immune system has been shown to further contribute to the activation of CLL cells. However, responses to TLR9 engagement are not uniform, but diametrically opposed with cell death in some patients and cell proliferation in others. We now provide evidence that heterogeneous responses to TLR agonists are related to differences in the ability of CLL cells to activate the BCR-associated kinase Syk. Notably, expression of ZAP-70 appears to be of crucial importance for TLR9-mediated activation of Syk. We show that the activation of Syk provides an antiapoptotic signal, which is independent of Mcl-1, Bcl-2, and Bcl-XL, but related to the degradation of the proapoptotic Bim. Mechanistically, TLR9-mediated antiapoptotic signals in ZAP-70-positive CLL trigger secretion of immunoglobulin M, which then serves as (auto-) antigen for a prosurvival BCR signal. Thus, our data show that single activation of the innate immune receptor TLR9 is sufficient to fully engage BCR signaling in ZAP-70-positive CLL, protecting malignant cells from apoptosis. We conclude that the integration of TLR signaling into an adaptive immune response can further promote survival of CLL cells and may contribute to the unfavorable prognosis of ZAP-70-positive CLL.


Subject(s)
Adaptive Immunity , Immunity, Innate , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , ZAP-70 Protein-Tyrosine Kinase/immunology , B-Lymphocytes/immunology , B-Lymphocytes/pathology , Cell Line , Cell Survival , Humans , Intracellular Signaling Peptides and Proteins/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Protein-Tyrosine Kinases/immunology , Receptors, Antigen, B-Cell/immunology , Signal Transduction , Syk Kinase , Toll-Like Receptor 9/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...